AgingResearch.NewsJoin free

NeuroSense Therapeutics

CompanyIsraelFounded 2017

NeuroSense Therapeutics develops one asset, in phase 2 (Ciprofloxacin/Celecoxib in ALS). Mostly small molecule acting on inflammation and PTGS2; based in Israel, founded in 2017.

1
Asset
Furthest stage
Phase 2
4
Trials
0
Signals

Pipeline

1

  • Ciprofloxacin/Celecoxib

    Fixed-dose combination of ciprofloxacin and celecoxib targeting neuroinflammation and RNA processing in neurodegeneration.

    Phase 2, Small molecule, Inflammation, PTGS2, ALS, amyotrophic lateral sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials4
  • Similar companies6

Intelligence